司美格鲁肽治疗NIT评估MASH的随机对照试验
这项多中心随机双盲安慰剂对照52周试验纳入55例疑似高危MASH患者,评估司美格鲁肽2.4mg每周皮下注射的疗效。主要终点FAST评分变化在司美格鲁肽组显著优于安慰剂(-0.28 vs -0.12,p=0.002),且体重下降≥5%、MRI-PDFF下降≥30%的比例更高。胃肠道不良事件常见但两组无显著差异。
要点
- 司美格鲁肽显著降低FAST评分,优于安慰剂(-0.28 vs -0.12,p=0.002)
- 司美格鲁肽组体重下降≥5%和MRI-PDFF下降≥30%比例显著更高
- FAST、ALT、AST和MRI-PDFF可用于监测治疗反应
核心结论
- 基于NIT识别高危MASH患者并给予司美格鲁肽治疗是可行且有效的。
- FAST、ALT、AST和MRI-PDFF可用于监测司美格鲁肽的治疗反应。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照52周试验。
- 共随机55例符合AASLD标准MASLD且BMI≥27 kg/m²,或BMI≥25 kg/m²伴糖尿病前期/2型糖尿病且VCTE肝硬度≥8 kPa、FAST评分≥0.5的患者。
- 随机接受司美格鲁肽2.4 mg每周皮下注射或安慰剂。
主要发现
- 司美格鲁肽组FAST评分降幅显著大于安慰剂组(-0.28 vs -0.12,p=0.002)。
- 司美格鲁肽组体重下降≥5%比例显著更高(64% vs 8.3%,p<0.001)。
- 司美格鲁肽组MRI-PDFF下降≥30%比例显著更高(60% vs 17%,p=0.047)。
- 司美格鲁肽组ALT、AST、GGT、HbA1c和LDL胆固醇降幅显著更大(p<0.05)。
- 胃肠道相关不良事件常见但两组无显著差异(p=0.59)。
关键数值与推荐
- 纳入标准:AASLD标准MASLD,BMI≥27 kg/m²,或BMI≥25 kg/m²伴糖尿病前期/2型糖尿病且VCTE肝硬度≥8 kPa、FAST评分≥0.5。
- 主要终点:治疗结束时FAST评分较基线变化。
- 其他终点:体重、MRI-PDFF、ALT和HbA1c变化。
临床怎么用
- 可基于NIT(VCTE肝硬度、FAST评分)筛选适合司美格鲁肽治疗的高危MASH患者。
- 治疗中可用FAST、ALT、AST和MRI-PDFF监测治疗反应。
局限性
- 样本量较小(55例),需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Non-invasive test (NIT)-based assessment of eligibility and treatment response with semaglutide is needed to inform clinical practice guidance. Therefore, utilising a randomised, placebo-controlled study design, we evaluated the utility of NITs to assess eligibility and treatment response in patients with suspected at-risk MASH randomised to semaglutide versus placebo. METHODS: In this multicentre, randomised, double-blind placebo-controlled 52-week trial, patients meeting AASLD criteria for MASLD with BMI ≥ 27 kg/m2, or BMI ≥ 25 kg/m2 and prediabetes or type 2 diabetes with liver stiffness by VCTE ≥ 8 kPa and a FAST score ≥ 0.5 were randomised to either semaglutide 2.4 mg subcutaneously weekly or placebo. The primary outcome was change in the FAST score at end of treatment from baseline. Other endpoints included changes in body weight, MRI-PDFF, ALT and HbA1c. RESULTS: Fifty-five participants were randomised (55% women, 20% with diabetes). Mean (SD) age, BMI, and FAST at baseline were 48.8 (14) years, 40.2 (15) kg/m2, 0.62 (0.12), respectively. The semaglutide group had a significantly greater reduction in FAST compared with placebo (-0.28 vs. -0.12; p = 0.002). More semaglutide recipients achieved ≥ 5% weight loss (64% vs. 8.3%; p < 0.001) and ≥ 30% reduction in MRI-PDFF (60% vs. 17%; p = 0.047). Semaglutide led to a significantly greater reduction in ALT, AST, GGT, HbA1c and LDL cholesterol (p < 0.05). Gastrointestinal-related adverse events were common but not significantly different between the two groups (p = 0.59). CONCLUSIONS: A NIT-based approach to identify at-risk MASH patients for semaglutide treatment is feasible and effective. This study provides RCT data showing that FAST, ALT, AST and MRI-PDFF can be used to monitor treatment response.
引用
- Ajmera V, Vuppalanchi R, Khalili M, et al. Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA). Aliment Pharmacol Ther. 2026. PMID: 41527269. doi:10.1111/apt.70516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。